Last updated: 2026-09-05 13:21:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aktis Oncology, Inc. (AKTS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.09, with a market capitalization of $1.50B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $34.19. This page covers its latest market performance, valuation, price trends and company information.
$1.50B | |
$26.18 | |
$34.19 | |
$0.03 | |
$26.65 | |
144.95K | |
-- | |
-- | |
$34.19 | |
$14.72 | |
-- | |
-- |
Aktis Oncology, Inc. (AKTS) last closed at $26.65 as of 2026-09-04 23:31:00, unchanged from the previous close of $26.65.
During the latest regular trading session, AKTS traded between $0.03 and $34.19, with a volume of 144.95K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Aktis Oncology, Inc. (AKTS) moved from $25.57 to $27.09, representing a gain of 5.94% ($1.52).
The stock traded between $22.92 and $30.89 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 219.41 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.5%
AKTS is currently trading at $27.09, placing it 63.5% of the way from its 52-week low of $14.72 to its 52-week high of $34.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 79 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aktis Oncology, Inc. (AKTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.